RSC
NBIX icon

Red Spruce Capital’s Neurocrine Biosciences NBIX Stock Holding History

Red Spruce Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.81M Sell
16,693
-516
-3% -$76.6K 0.98% 35
2026
Q1 		$2.27M Buy
17,209
+54
+0.3% +$7.17K 0.93% 36
2025
Q4 		$2.43M Sell
17,155
-213
-1% -$30.9K 0.97% 37
2025
Q3 		$2.44M Buy
17,368
+1,791
+11% +$243K 0.99% 36
2025
Q2 		$1.96M Hold
15,577
– – 0.85% 39
2025
Q1 		$1.72M Sell
15,577
-344
-2% -$43.6K 0.81% 46
2024
Q4 		$2.17M Buy
15,921
+15
+0.1% +$1.85K 0.96% 35
2024
Q3 		$1.83M Sell
15,906
-244
-2% -$33.5K 0.83% 44
2024
Q2 		$2.22M Buy
16,150
+124
+0.8% +$17K 1.03% 33
2024
Q1 		$2.21M Hold
16,026
– – 1.03% 33
2023
Q4 		$2.11M Buy
16,026
+101
+0.6% +$11.6K 1.08% 32
2023
Q3 		$1.79M Hold
15,925
– – 1.02% 36
2023
Q2 		$1.5M Buy
15,925
+261
+2% +$25.5K 0.81% 48
2023
Q1 		$1.59M Buy
15,664
+386
+3% +$40.2K 0.93% 41
2022
Q4 		$1.82M Buy
15,278
+75
+0.5% +$8.79K 1.16% 30
2022
Q3 		$1.61M Buy
15,203
+121
+0.8% +$12.3K 1.13% 32
2022
Q2 		$1.47M Buy
15,082
+228
+2% +$21K 0.98% 35
2022
Q1 		$1.39M Buy
14,854
+1,915
+15% +$162K 0.79% 48
2021
Q4 		$1.1M Buy
12,939
+1,193
+10% +$110K 0.6% 57
2021
Q3 		$1.13M Sell
11,746
-105
-0.9% -$9.92K 0.66% 56
2021
Q2 		$1.15M Hold
11,851
– – 0.68% 55
2021
Q1 		$1.15M Buy
11,851
+285
+2% +$29.9K 0.73% 50
2020
Q4 		$1.11M Buy
11,566
+422
+4% +$40.8K 0.77% 48
2020
Q3 		$1.07M Buy
11,144
+1,235
+12% +$143K 0.87% 44
2020
Q2 		$1.21M Buy
9,909
+36
+0.4% +$3.98K 1.03% 37
2020
Q1 		$855K Sell
9,873
-53
-0.5% -$5.19K 0.89% 44
2019
Q4 		$1.07M Buy
+9,926
New +$1.04M 0.89% 52

Other funds holding NBIX

Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PBBUPS
PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
EA
Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return
P
PensionDanmark Copenhagen O, Denmark $12B AUM
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Red Spruce Capital's NBIX Position: Q2 2026 in Review

Red Spruce Capital reduced its Neurocrine Biosciences (NBIX) stake by 3% in Q2 2026, selling an estimated $76.6K and leaving 16,693 shares worth $2.81M. The position accounts for 0.98% of the portfolio, ranked #35.

Red Spruce Capital first reported a position in NBIX in Q4 2019 and has held it in 27 quarters since. 108 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Red Spruce Capital held 16,693 shares of Neurocrine Biosciences worth $2.81M as of Q2 2026.
  • Red Spruce Capital sold 516 Neurocrine Biosciences shares in Q2 2026, an estimated $76.6K.
  • Neurocrine Biosciences made up 0.98% of Red Spruce Capital's portfolio in Q2 2026, its #35 holding.
  • Red Spruce Capital first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 27 quarters since.
  • 108 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Red Spruce Capital's 13F filing for Q2 2026, filed 7 Jul 2026.